Activity was in full swing at the Phase II API and drug product construction site of Shandong Longzen Pharmaceutical Co., Ltd (hereinafter referred to as "Longzen”). on August 23rd, 2022. The company's production sections consist of API manufacturing, as well as refining-drying-packing, all of which were operating smoothly and in an organized fashion.
Longzen has set its sights on achieving full production by 2025, with a projected output value of 5 billion yuan and a profit of 1.5 billion yuan. The expansion is expected to generate around 1,500 job opportunities.
